Azacytidine clinical trials
Azacytidine is named as an intervention in 13 current clinical trials in our China, Mexico, Canada, Israel, USA, Egypt, Japan and Singapore registers. 9 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is National Cancer Institute (NCI) (7). The most-studied condition is Acute Myeloid Leukemia.
Patient leaflets for Azacytidine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Azacytidine
13 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Azacytidine
23 conditionsAll 23 conditions
| Condition (as registered) | Trials |
|---|---|
| Acute Myeloid Leukemia | 6 |
| Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | 2 |
| Acute Myeloid Leukemia Post Cytotoxic Therapy | 2 |
| Acute Myeloid Leukemia, Myelodysplasia-Related | 2 |
| Hematologic Malignancies | 1 |
| Newly Diagnosed Acute Myeloid Leukemia (AML) | 1 |
| Elderly Patients | 1 |
| Relapsed Peripheral T-Cell Lymphomas | 1 |
| Refractory Peripheral T-Cell Lymphomas | 1 |
| First Line Therapy | 1 |
| DLBCL - Diffuse Large B Cell Lymphoma | 1 |
| Relapsed/Refractory Acute Myeloid Leukemia | 1 |
| Chronic Myelomonocytic Leukemia | 1 |
| Chronic Myelomonocytic Leukemia-1 | 1 |
| Chronic Myelomonocytic Leukemia-2 | 1 |
| Myelodysplastic Syndrome | 1 |
| Adult Acute Megakaryoblastic Leukemia | 1 |
| Adult Acute Monoblastic Leukemia | 1 |
| Adult Acute Monocytic Leukemia | 1 |
| Adult Nasal Type Extranodal NK/T-Cell Lymphoma | 1 |
| Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | 1 |
| Recurrent Nasopharyngeal Undifferentiated Carcinoma | 1 |
| Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 7 |
| Chinese PLA General Hospital | 3 |
| Sellas Life Sciences Group | 1 |
| Navy General Hospital, Beijing | 1 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Azacytidine trials
How many clinical trials are testing Azacytidine?
13 current trials in our China, Mexico, Canada, Israel, USA, Egypt, Japan and Singapore registers name Azacytidine as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Azacytidine trials recruiting patients?
Yes. 9 of the 13 trials are recruiting: 5 with sites in China, 4 with sites in Mexico, 4 with sites in Canada, 3 with sites in Israel, 1 with sites in USA and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Azacytidine clinical trials?
National Cancer Institute (NCI) (7), Chinese PLA General Hospital (3), Sellas Life Sciences Group (1) and Navy General Hospital, Beijing (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Azacytidine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Azacytidine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Azacytidine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.